ELVNEnliven Therapeutics, Inc.

$40.98+116% 1Y

$40.98

$15.1452 weeks$61.15

ELVN in its own filings

Nothing in ELVN's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

129

Events found in the filings · across 788 filings · the record starts in 2019

Hard flags: none
Hard flags
Most recent filing: Aug 5, 2026
Most recent filing · Form 10-Q
Record starts: Sep 11, 2019
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 11, 2026
Change in certifying accountanthistorical: 2023-03-01
SEC comment-letter activity20 occurrences: 2024-04-26

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 5, 2026Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update.Earnings release · press release
Jun 12, 2026On June 11, 2026, Enliven Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the “Representatives”) of the several underwriters named therein …Material agreement entered · Form 8-K
Jun 11, 2026On June 11, 2026, the Company announced updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with CML and key outcomes from the Company’s End-of-Phase 1 meeting with the U.S. Food and Drug Administration (the “FDA”)Regulation FD disclosure · Form 8-K
Jun 10, 2026Enliven Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 9, 2026.Charter/bylaw amendment or fiscal-year change · Form 8-K
May 7, 2026Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update.Earnings release · press release
Mar 3, 2026Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update.Earnings release · press release
Jan 7, 2026Appointment of Director On January 6, 2026, the board of directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Scott Garland to serve as a Class I director, with a term expiring at the Company’s 2027 annual meeting of stockholders, and as the Chair of the Nominating and Corporate Governance …Director or officer change · Form 8-K
Dec 11, 2025Announcement of New Chief Executive Officer and Director On December 11, 2025, Enliven Therapeutics, Inc. (the “Company”) announced the appointment of Richard Fair as the Company’s President and Chief Executive Officer and as a member of the board of directors (the “Board”) of the Company, effective as of December 11 …Director or officer change · Form 8-K
Nov 12, 2025Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update.Earnings release · press release